利塞膦酸钠可减少非骨水泥全髋关节置换术后的骨吸收：系统评价和荟萃分析。
Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty: A systematic review and meta-analysis.
机构信息
Department of Joint Surgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, 315020, China.
Department of Joint Surgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, 315020, China.
出版信息
Int J Surg. 2018 Apr;52:189-200. doi: 10.1016/j.ijsu.2018.02.007. Epub 2018 Feb 12.
OBJECTIVE
To examine the effects of risedronate for reducing periprosthetic bone loss after total hip arthroplasty (THA).
METHODS
Two reviewers performed an electronic literature search for randomized controlled trial (RCTs) evaluating the risedronate in the management of periprosthetic bone loss after primary THA. The electronic databases include PubMed, Medline, Embase, Web of Science and the Cochrane Library from inception to January 2018. We assessed the risk of bias using the Cochrane risk-of-bias tool. STATA 14.0 was used to perform the meta-analysis.
RESULTS
Four RCTs were included in our study. Current meta-analysis indicated that postoperative reduciton of periprosthetic BMD in the risedronate group was significantly lower than that in the placebo group in zones 1, 2, 3, 4, 6, and 7. There was no increased risk of adverse effects.
CONCLUSION
The administration of risedronate was associates with a significantly improved periprosthetic BMD after primary THA. No increased risk of adverse events were observed. Higher quality RCTs are still required for further research.
目的
研究利塞膦酸钠对全髋关节置换术后（THA）假体周围骨丢失的影响。
方法
两位审查员对评价利塞膦酸钠在原发性 THA 后管理假体周围骨丢失的随机对照试验（RCT）进行了电子文献检索。电子数据库包括从成立到 2018 年 1 月的 PubMed、Medline、Embase、Web of Science 和 Cochrane Library。我们使用 Cochrane 偏倚风险工具评估偏倚风险。使用 STATA 14.0 进行荟萃分析。
结果
我们的研究纳入了 4 项 RCT。当前的荟萃分析表明，利塞膦酸钠组在区域 1、2、3、4、6 和 7 中的术后假体周围 BMD 降低显著低于安慰剂组。没有增加不良事件的风险。
结论
原发性 THA 后，利塞膦酸钠的应用与假体周围 BMD 的显著改善相关，未观察到不良事件风险增加。仍需要更高质量的 RCT 进行进一步研究。
Zotero 插件